Warfarin Genotyping Reduces Hospitalization Rates Results From the MM-WES (Medco-Mayo Warfarin Effectiveness Study)

被引:241
作者
Epstein, Robert S. [1 ]
Moyer, Thomas P. [2 ]
Aubert, Ronald E. [1 ]
O'Kane, Dennis J. [2 ]
Xia, Fang [1 ]
Verbrugge, Robert R. [1 ]
Gage, Brian F. [3 ]
Teagarden, J. Russell [1 ]
机构
[1] Medco Hlth Solut Inc, Dept Med & Analyt Affairs, Franklin Lakes, NJ 07417 USA
[2] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
[3] Washington Univ, Dept Internal Med, St Louis, MO USA
关键词
warfarin; genotyping; pharmacogenomics; comparative effectiveness; BLEEDING COMPLICATIONS; VKORC1; ANTICOAGULATION; ACCURACY; TRIAL; RISK;
D O I
10.1016/j.jacc.2010.03.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives This study was designed to determine whether genotype testing for patients initiating warfarin treatment will reduce the incidence of hospitalizations, including those due to bleeding or thromboembolism. Background Genotypic variations in CYP2C9 and VKORC1 have been shown to predict warfarin dosing, but no large-scale studies have prospectively evaluated the clinical effectiveness of genotyping in naturalistic settings across the U.S. Methods This national, prospective, comparative effectiveness study compared the 6-month incidence of hospitalization in patients receiving warfarin genotyping (n = 896) versus a matched historical control group (n = 2,688). To evaluate for temporal changes in the outcomes of warfarin treatment, a secondary analysis compared outcomes for 2 external control groups drawn from the same 2 time periods. Results Compared with the historical control group, the genotyped cohort had 31% fewer hospitalizations overall (adjusted hazard ratio [HR]: 0.69, 95% confidence interval [CI]: 0.58 to 0.82, p < 0.001) and 28% fewer hospitalizations for bleeding or thromboembolism (HR: 0.72, 95% CI: 0.53 to 0.97, p = 0.029) during the 6-month follow-up period. Findings from a per-protocol analysis were even stronger: 33% lower risk of all-cause hospitalization (HR: 0.67, 95% CI: 0.55 to 0.81, p < 0.001) and 43% lower risk of hospitalization for bleeding or thromboembolism (HR: 0.57, 95% CI: 0.39 to 0.83, p = 0.003) in patients who were genotyped. During the same period, there was no difference in outcomes between the 2 external control groups. Conclusions Warfarin genotyping reduced the risk of hospitalization in outpatients initiating warfarin. (The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings [MHSMayoWarf1]; NCT00830570) (J Am Coll Cardiol 2010; 55: 2804-12) (C) 2010 by the American College of Cardiology Foundation
引用
收藏
页码:2804 / 2812
页数:9
相关论文
共 28 条
  • [1] Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation
    Anderson, Jeffrey L.
    Horne, Benjamin D.
    Stevens, Scott M.
    Grove, Amanda S.
    Barton, Stephanie
    Nicholas, Zachery P.
    Kahn, Samera F. S.
    May, Heidi T.
    Samuelson, Kent M.
    Muhlestein, Joseph B.
    Carlquist, John F.
    [J]. CIRCULATION, 2007, 116 (22) : 2563 - 2570
  • [2] Accuracy of coding for possible warfarin complications in hospital discharge abstracts
    Arnason, T.
    Wells, P. S.
    van Walraven, C.
    Forster, A. J.
    [J]. THROMBOSIS RESEARCH, 2006, 118 (02) : 253 - 262
  • [3] A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin - A randomized, controlled trial
    Beyth, RJ
    Quinn, L
    Landefeld, CS
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 133 (09) : 687 - 695
  • [4] Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors
    Birman-Deych, E
    Waterman, AD
    Yan, Y
    Nilasena, DS
    Radford, MJ
    Gage, BF
    [J]. MEDICAL CARE, 2005, 43 (05) : 480 - 485
  • [5] *BRIST MYERS SQUIB, 2010, COUM TABL WARF SOD T
  • [6] National surveillance of emergency department visits for outpatient adverse drug events
    Budnitz, Daniel S.
    Pollock, Daniel A.
    Weidenbach, Kelly N.
    Mendelsohn, Aaron B.
    Schroeder, Thomas J.
    Annest, Joseph L.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (15): : 1858 - 1866
  • [7] Genetic testing for warfarin dosing? Not yet ready for prime time
    Bussey, Henry I.
    Wittkowsky, Ann K.
    Hylek, Elaine M.
    Walker, Marie B.
    [J]. PHARMACOTHERAPY, 2008, 28 (02): : 141 - 143
  • [8] CYP4F2 genetic variant alters required warfarin dose
    Caldwell, Michael D.
    Awad, Tarif
    Johnson, Julie A.
    Gage, Brian F.
    Falkowski, Mat
    Gardina, Paul
    Hubbard, Jason
    Turpaz, Yaron
    Langaee, Taimour Y.
    Eby, Charles
    King, Cristi R.
    Brower, Amy
    Schmelzer, John R.
    Glurich, Ingrid
    Vidaillet, Humberto J.
    Yale, Steven H.
    Zhang, Kai Qi
    Berg, Richard L.
    Burmester, James K.
    [J]. BLOOD, 2008, 111 (08) : 4106 - 4112
  • [9] CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation:: A prospective randomized controlled study
    Caraco, Y.
    Blotnick, S.
    Muszkat, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (03) : 460 - 470
  • [10] Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation
    Eckman, Mark H.
    Rosand, Jonathan
    Greenberg, Steven M.
    Gage, Brian F.
    [J]. ANNALS OF INTERNAL MEDICINE, 2009, 150 (02) : 73 - U31